From genotype to phenotype in coronary artery disease
Ischemic heart disease represents the leading cause of death worldwide and is a consequence of coronary artery disease and myocardial infarction. Despite advances in the treatment of risk factors, the prevalence has increased over the past 20 years. New preventive strategies that address previously unknown pathophysiological processes are therefore required. A variety of novel potential targets have been identified in genome-wide association studies that aimed to elucidate the genetic basis of another risk factor: positive family history. My group focuses on the investigation of the molecular mechanisms and the therapeutic potential of such novel targets. Here, I will discuss recent published and unpublished work of my group in, e.g., nitric-oxide signaling and remodeling of the extracellular matrix. Lastly, I will discuss novel strategies to improve the outcome of patients already suffering from coronary artery disease.
